AI-Cybernetics Collaboration Revolutionizes Pharma

Conduit Pharmaceuticals has partnered with SARBORG Limited to integrate advanced AI and cybernetics into its operations. The collaboration focuses on improving drug repurposing, discovery, clinical trial monitoring, and asset management by reducing human error, accelerating timelines, and cutting costs. Sarborg’s platform will provide predictive models and real-time dashboards to enhance decision-making and optimize drug development processes.

Conduit gains a perpetual, royalty-free right to the technology developed through the partnership, emphasizing innovation and efficiency. CEO Dr. David Tapolczay highlights this as a transformative step toward revolutionizing drug development strategies.